DK2836200T3 - Termoreversible hydrogelpræparater til anvendelse i behandlingen af lidelser i urothelium - Google Patents

Termoreversible hydrogelpræparater til anvendelse i behandlingen af lidelser i urothelium Download PDF

Info

Publication number
DK2836200T3
DK2836200T3 DK13775035.2T DK13775035T DK2836200T3 DK 2836200 T3 DK2836200 T3 DK 2836200T3 DK 13775035 T DK13775035 T DK 13775035T DK 2836200 T3 DK2836200 T3 DK 2836200T3
Authority
DK
Denmark
Prior art keywords
urothelium
disorders
treatment
thermoreversible hydrogel
hydrogel preparations
Prior art date
Application number
DK13775035.2T
Other languages
English (en)
Inventor
Marina Konorty
Michal Jeshurun
Gil Hakim
Original Assignee
Urogen Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urogen Pharma Ltd filed Critical Urogen Pharma Ltd
Application granted granted Critical
Publication of DK2836200T3 publication Critical patent/DK2836200T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK13775035.2T 2012-04-08 2013-04-08 Termoreversible hydrogelpræparater til anvendelse i behandlingen af lidelser i urothelium DK2836200T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261621525P 2012-04-08 2012-04-08
PCT/IL2013/050314 WO2013153550A2 (en) 2012-04-08 2013-04-08 Reverse thermal hydrogel preparations for use in the treatment of disorders of the urothelium

Publications (1)

Publication Number Publication Date
DK2836200T3 true DK2836200T3 (da) 2020-09-21

Family

ID=49328256

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13775035.2T DK2836200T3 (da) 2012-04-08 2013-04-08 Termoreversible hydrogelpræparater til anvendelse i behandlingen af lidelser i urothelium

Country Status (7)

Country Link
EP (1) EP2836200B1 (da)
CN (1) CN104379127A (da)
DK (1) DK2836200T3 (da)
ES (1) ES2821098T3 (da)
IL (1) IL236000B (da)
RU (1) RU2635466C2 (da)
WO (1) WO2013153550A2 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2622064B1 (en) 2010-10-01 2019-05-29 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3096804B1 (en) * 2014-01-20 2019-12-04 Bioteck S.p.A. Method of making a hydrogel, hydrogel and formulation for carriers and/or substitute of connective tissues obtained using such method
CN105012961B (zh) * 2014-04-17 2020-07-21 燃点(南京)生物医药科技有限公司 稳定的药物组合物及其制备方法
US9943576B2 (en) * 2014-04-30 2018-04-17 Allergan, Inc. Formulations of biologics for intravesical instillation
CA2955492A1 (en) * 2014-07-31 2016-02-04 Allergan, Inc. Formulations of biologics for intravesical instillation
JP7265989B2 (ja) * 2016-10-25 2023-04-27 ウロゲン ファーマ リミテッド 体腔の免疫調節治療
WO2018183624A1 (en) 2017-03-29 2018-10-04 The Regents Of The University Of Colorado, A Body Corporate Reverse thermal gels and their use as vascular embolic repair agents
ES2769059T3 (es) * 2017-05-12 2020-06-24 Farco Gmbh Composición de instilación de la vejiga que contiene sulfato de condonitina (20 mg/ml), ácido hialurónico (16 mg/ml) y buffer de fosfato (pH 6,1 a 7,9) con mayor estabilidad de almacenamiento para el tratamiento de la cistitis
EP3675900A4 (en) * 2017-08-28 2021-05-05 Revance Therapeutics, Inc. TRANSMUCOSAL BOTULINUM TOXIN COMPOSITIONS, KITS, AND METHODS FOR TREATMENT OF BLADDER DISORDER
EP3470054B1 (en) * 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
CN111110683B (zh) * 2018-10-31 2023-08-15 广东东阳光药业股份有限公司 一种索利那新掩味组合物及其制备方法
WO2020222139A1 (en) * 2019-04-30 2020-11-05 Trigone Pharma Ltd. Formulations and methods for drug instillation into the bladder and treatment of bladder ailments
KR20240089461A (ko) * 2021-10-17 2024-06-20 트라이곤 파마 엘티디. 비뇨기 방광 내로 약물 점적을 위한 조성물 및 방법
AU2022405465A1 (en) * 2021-12-08 2024-06-20 The Johns Hopkins University Hypotonic gel-forming formulations with enhanced rheological properties
KR20240067734A (ko) * 2022-11-09 2024-05-17 원광대학교산학협력단 치주질환 치료, 개선 및 예방용 온도감응성 하이드로겔 조성물 및 이의 제조방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069411A (en) * 1960-04-14 1962-12-18 Penick & Ford Ltd Inc Modification of starch with phosphates and amides
ATE552006T1 (de) * 1997-07-15 2012-04-15 Univ Colorado Regents Verwendung einer neurotoxintherapie zur behandlung urologischer und zugehöriger erkrankungen
MY130475A (en) * 2000-08-25 2007-06-29 Contura As Polyacrylamide hydrogel and its use as an endoprosthesis
US20040009212A1 (en) * 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
CA2530407A1 (en) * 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
AU2004267910B2 (en) * 2003-08-29 2011-01-06 Veloxis Pharmaceuticals, Inc. Solid dispersions comprising tacrolimus
GB0328060D0 (en) * 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
WO2006065234A1 (en) * 2004-12-10 2006-06-22 University Of Pittsburgh Use of lipid and hydrogel vehicles for treatment and drug delivery
US8679484B2 (en) * 2005-03-02 2014-03-25 Polyrizon Ltd. Method for removal of toxins from mucosal membranes
EP1893174A2 (en) * 2005-05-10 2008-03-05 Cytophil, Inc. Injectable hydrogels and methods of making and using same
WO2008030638A2 (en) * 2006-05-16 2008-03-13 Mayo Foundation For Medical Education And Research Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US8318817B2 (en) * 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
WO2011018800A2 (en) * 2009-08-13 2011-02-17 Fdc Limited A novel in-situ gel forming solution for ocular drug delivery
ES2732150T3 (es) * 2010-01-20 2019-11-20 Urogen Pharma Ltd Material y método para tratar cavidades internas
WO2013011504A1 (en) * 2011-07-20 2013-01-24 Theracoat Ltd. Materials and method for treating internal body cavities

Also Published As

Publication number Publication date
IL236000B (en) 2022-02-01
CN104379127A (zh) 2015-02-25
EP2836200A2 (en) 2015-02-18
WO2013153550A3 (en) 2013-12-27
ES2821098T3 (es) 2021-04-23
RU2635466C2 (ru) 2017-11-13
WO2013153550A2 (en) 2013-10-17
EP2836200A4 (en) 2015-09-02
EP2836200B1 (en) 2020-07-15
IL236000A0 (en) 2015-01-29
RU2014144727A (ru) 2016-05-27

Similar Documents

Publication Publication Date Title
DK2836200T3 (da) Termoreversible hydrogelpræparater til anvendelse i behandlingen af lidelser i urothelium
LTC3057969I2 (lt) Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit
DK2938740T3 (da) Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
DK3329884T3 (da) Implanterbar indretning til behandling af glaukom
DK2830662T3 (da) Fremgangsmåder til behandlng af hårtabsforstyrrelser
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
SG11201500685PA (en) Warm-cool beauty treatment device
DK2815769T3 (da) Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet
DK2838539T3 (da) Østrogenderivater til anvendelse i behandlingen af neurologiske forstyrrelser
DK2830645T3 (da) Neuregulin til anvendelse i behandling af perifær nervelæsion
DK2782566T3 (da) L-serin til anvendelse ved behandling af neurodegenerative lidelser
IL235127A (en) Hpn-100 for use in the treatment of nitrogen-related diseases
FR2993464B1 (fr) Pansement interface autoporte
BR112014029487A2 (pt) método para o tratamento cosmético
DK2705847T3 (da) Sammensætning til behandling af psoriasis
DK3044229T3 (da) Peptider til anvendelse i behandlingen af oral mucositis
DK3049100T3 (da) Modificerede fibroblastvækstfaktorer-1 til behandling af øjenlidelser
DK2897681T3 (da) Medicinsk applikator
ITRM20120530A1 (it) Compounds for use in the treatment of parasitic diseases
DK2976101T3 (da) Behandlingsfremgangsmåde
SMT201600363B (it) Modafinil per l’uso nel trattamento di ***omani